Hangzhou AGS Medtech Co (SHSE:688581) Research & Development: ¥78.6 Mil (TTM As of Mar. 2026)


SHSE:688581 Hangzhou AGS Medtech Co Ltd SHSE:688581
87 GF Score
Price ¥55.70
GF Value ¥74.30
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Hangzhou AGS Medtech Co Research & Development?

Hangzhou AGS Medtech Co SHSE:688581 -0.89% 87 Research & Development is ¥78.6 Mil as of Mar. 2026. GuruFocus rates SHSE:688581 with a GF Score™ of 87/100 and a GF Value™ of ¥74.30 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hangzhou AGS Medtech Co's Research & Development for the three months ended in Mar. 2026 was ¥15.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥78.6 Mil.

Hangzhou AGS Medtech Co  (SHSE:688581) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hangzhou AGS Medtech Co Research & Development Related Terms

Hangzhou AGS Medtech Co Research & Development Historical Data

* Premium members only.

The historical data trend for Hangzhou AGS Medtech Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou AGS Medtech Co Research & Development Chart

Hangzhou AGS Medtech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 24.19 31.46 41.25 59.21 75.90

Hangzhou AGS Medtech Co Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.99 21.47 22.70 18.74 15.65
SHSE:688581
87GF Score
Hangzhou AGS Medtech Co Ltd SHSE:688581
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou AGS Medtech Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥78.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥78.6 Mil mean?
Hangzhou AGS Medtech Co (SHSE:688581) has a Research & Development of ¥78.6 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hangzhou AGS Medtech Co and its competitors.
Is Hangzhou AGS Medtech Co's Research & Development too high?
Hangzhou AGS Medtech Co's current Research & Development is ¥78.6 Mil. Overall, Hangzhou AGS Medtech Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou AGS Medtech Co's Research & Development compare to ABT and SYK?
Hangzhou AGS Medtech Co's Research & Development of ¥78.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hangzhou AGS Medtech Co and its competitors. Hangzhou AGS Medtech Co's current Research & Development is ¥78.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou AGS Medtech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou AGS Medtech Co (SHSE:688581) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥74.30, compared to a current price of ¥55.70 — trading 25% below its estimated fair value. The current Research & Development is ¥78.6 Mil. Hangzhou AGS Medtech Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hangzhou AGS Medtech Co (SHSE:688581), the current Research & Development is ¥78.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hangzhou AGS Medtech Co (SHSE:688581) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou AGS Medtech Co stock appears to be undervalued. The current stock price of ¥55.70 is trading 25% below its estimated GF Value™ of ¥74.30. GuruFocus considers Hangzhou AGS Medtech Co to be Modestly Undervalued.

Key valuation signals for SHSE:688581:

  • Research & Development: ¥78.6 Mil
  • GF Value™: ¥74.30 vs. price of ¥55.70 (25% below fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688581 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hangzhou AGS Medtech Co Business Description

Address No. 389 Xingzhong Road, Linping District, Zhejiang Province, Hangzhou, CHN, 311199
Hangzhou AGS Medtech Co Ltd is engaged in Research & Development, production, and sales of endoscopic minimally invasive diagnosis and treatment devices. The company upholds the core values of create, insist, share, and provide patients and clinicians with safer and more efficient minimally invasive endoscopic devices, helping patients reduce pain and medical costs.
87GF Score

Get the complete analysis for SHSE:688581

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥55.70
Price
¥74.30
GF Value